KeyBanc lowered the firm’s price target on Inspire Medical (INSP) to $216 from $234 and keeps an Overweight rating on the shares. The firm believes underlying MedTech trends remain mostly positive heading into Q1 earnings season, but is lowering several price targets to reflect macro concerns around the potential impact of tariffs as well as an increased risk of recession.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP: